Skip to main content
. 2024 Sep 10;110(21):e324052. doi: 10.1136/heartjnl-2024-324052

Figure 3. Probability that lifetime statin therapy is cost-effective in categories by prior cardiovascular disease, sex and pre-treatment LDL cholesterol level. The probability that the treatment scenario provides the highest QALYs gain at the particular threshold of cost-effectiveness plotted. CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; QALY, quality-adjusted life years.

Figure 3